UK medicines agency head
This article was originally published in The Tan Sheet
Executive Summary
Alasdair Breckenridge, chairman of the Medicines Control Agency's Committee on the Safety of Medicines, named chair-designate of UK's Medicines & Healthcare Products Regulatory Agency, Department of Health announces Nov. 28. MHRA will consist of MCA and Medical Devices Agency and will become official in April 2003 (1"The Tan Sheet" June 17, 2002, In Brief). One of Breckenridge's first responsibilities will be to help appoint a chief exec of MHRA; last day to submit applications for the post was Nov. 20...
You may also be interested in...
UK health agency merger
Medicines Control Agency, Medical Devices Agency will merge into single, as-yet-unnamed entity next April due to increasing convergence in drug, medical device fields, Department of Health announces June 13. Systems and processes by which drugs are licensed, medical devices are controlled will not be affected, but merger will include creation of chairman post to serve as agency's authoritative figurehead and oversee strategic management. Agency also will have a chief executive; current MCA Chief Exec Keith Jones, MD, is leaving his post in October...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.